AIC to partner on study
By HME News Staff
Updated 9:26 AM CDT, Wed October 25, 2023
DALLAS – Advanced Infusion Care (AIC), a division of AIS Healthcare, will conduct a joint study with Grifols, a leading global provider of essential plasma-derived and transfusion medicines, to observe the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID). AIC and Grifols’ Satisfaction and Outcomes in Primary Immune Deficiency patients (SOPID) study will observe 60 patients across a three-month period who are beginning SCIG therapy. The purpose of the study is to determine if there are differences in patient experience and satisfaction with immunoglobulin treatments, which will help physicians, pharmacists and nurses ensure patients living with immunodeficiencies receive the therapy that best fits their medical and lifestyle needs. “Grifols has an impressive track record of producing innovative, high-quality medicines for patients living with chronic and rare diseases,” said Jud Hall, president, AIC. “We are proud to partner with their team to carry out a study that will continue advancing our quality of care to better serve individuals living with primary immune deficiencies through SCIG treatment.” AIC’s network of 180 nurses operates in 40 states, consistently delivering patient-specific, specialized in-home infusion services, including SCIG treatment.
Comments